{
    "nct_id": "NCT04606914",
    "official_title": "Single-Arm Phase II Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy with Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer Who Are Folate Receptor Α Positive",
    "inclusion_criteria": "* Patients must have biopsy-confirmed high grade serous epithelial ovarian cancer.\n* Patients must present with stage III or IV disease and be appropriate to receive neoadjuvant chemotherapy\n* Patients must be willing to provide an archival tumor tissue block or slides, or undergo procedure to obtain a new biopsy using a low-risk, medically routine procedure for immunohistochemistry (IHC) confirmation of FRα positivity\n* Patients must have a performance status of 0 or 1.\n* Patient's tumor must be positive for FRα expression as defined by a score of PS2+ intensity in >75% of cells\n* Patients must have adequate hematologic, liver and kidney functions defined as:\n* Absolute neutrophil count (ANC) ≥ 1.5 x 109/L (1,500/μL)\n* Platelet count ≥ 100 x 109/L (100,000/μL) without platelet transfusion in the prior 10 days\n* Hemoglobin ≥ 9.0 g/dL\n* Serum creatinine ≤ 1.5 x upper limit of normal (ULN)\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 x ULN\n* Serum bilirubin ≤ 1.5 x ULN (patients with documented diagnosis of Gilbert syndrome are eligible if total bilirubin < 3.0 x ULN)\n* Serum albumin ≥ 2 g/dL\n* Patients must be willing and able to sign the informed consent form (ICF) and to adhere to the protocol requirements\n* Women of childbearing potential (WCBP) must agree to use highly effective contraceptive method(s) (as defined in Section 5.8.6 while on MIRV and for at least 4 months after the last dose\n* WCBP must have a negative pregnancy test within the 4 days prior to the first dose of MIRV\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients who have previously been treated with a systemic anti-cancer therapy\n* Patients with low-grade serous, endometrioid, clear cell, or mucinous histology\n* Patients with active or chronic corneal disorders, history of corneal transplantation, or active ocular conditions requiring ongoing treatment/monitoring, such as uncontrolled glaucoma, wet age-related macular degeneration requiring intravitreal injections, active diabetic retinopathy with macular edema, macular degeneration, presence of papilledema, and /or monocular vision\n* Patients with serious concurrent illness or clinically relevant active infection, including, but not limited to the following:\n* History of hepatitis B or C infection (whether or not on active antiviral therapy)\n* History of human immunodeficiency virus (HIV) infection\n* Any other concurrent infectious disease requiring IV antibiotics within 2 weeks prior to the first dose of MIRV\n* Patients with a history of multiple sclerosis (MS) or other demyelinating disease and/or Lambert-Eaton syndrome (paraneoplastic syndrome)\n* Patients with clinically significant cardiac disease including, but not limited to, any of the following:\n* Myocardial infarction ≤ 6 months prior to first dose\n* Unstable angina pectoris\n* Uncontrolled congestive heart failure (New York Heart Association > class II)\n* Uncontrolled ≥ Grade 3 hypertension (per CTCAE)\n* Uncontrolled cardiac arrhythmias\n* Patients with a history of hemorrhagic or ischemic stroke within 6 months prior to enrollment\n* Patients with a history of cirrhotic liver disease (Child-Pugh Class B or C)\n* Patients with a previous clinical diagnosis of noninfectious interstitial lung disease (ILD), including noninfectious pneumonitis\n* Patients requiring use of folate-containing supplements (eg, folate deficiency)\n* Patients with prior hypersensitivity to monoclonal antibodies (mAb)\n* Women who are pregnant or breastfeeding\n* Patients who received prior treatment with MIRV or other FRα-targeting agents\n* Patients with untreated or symptomatic central nervous system (CNS) metastases\n* Patients with a history of other malignancy within 3 years prior to enrollment Note: patients with tumors with a negligible risk for metastasis or death (eg, adequately controlled basal-cell carcinoma or squamous-cell carcinoma of the skin, or carcinoma in situ of the cervix or breast) are eligible",
    "miscellaneous_criteria": ""
}